Andra AP-fonden’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-142,200
| Closed | -$7.7M | – | 414 |
|
|
2025
Q3 | $7.7M | Buy |
142,200
+105,000
| +282% | +$6M | 0.1% | 237 |
|
|
2025
Q2 | $2.04M | Buy |
37,200
+19,300
| +108% | +$1.14M | 0.03% | 350 |
|
|
2025
Q1 | $1.27M | Buy |
17,900
+6,700
| +60% | +$451K | 0.02% | 388 |
|
|
2024
Q4 | $736K | Sell |
11,200
-12,000
| -52% | -$804K | 0.01% | 369 |
|
|
2024
Q3 | $1.63M | Buy |
23,200
+4,800
| +26% | +$401K | 0.02% | 364 |
|
|
2024
Q2 | $1.51M | Buy |
+18,400
| New | +$1.53M | 0.03% | 361 |
|
|
2024
Q1 | – | Sell |
-49,400
| Closed | -$4.76M | – | 375 |
|
|
2023
Q4 | $4.76M | Sell |
49,400
-8,400
| -15% | -$743K | 0.25% | 174 |
|
|
2023
Q3 | $5.11M | Sell |
57,800
-14,400
| -20% | -$1.28M | 0.3% | 162 |
|
|
2023
Q2 | $6.26M | Sell |
72,200
-16,700
| -19% | -$1.57M | 0.16% | 309 |
|
|
2023
Q1 | $8.64M | Buy |
88,900
+11,100
| +14% | +$1.15M | 0.22% | 168 |
|
|
2022
Q4 | $8.05M | Sell |
77,800
-15,400
| -17% | -$1.45M | 0.24% | 131 |
|
|
2022
Q3 | $7.9M | Buy |
93,200
+6,400
| +7% | +$570K | 0.26% | 117 |
|
|
2022
Q2 | $7.19M | Buy |
+86,800
| New | +$6.91M | 0.21% | 197 |
|
|
2021
Q4 | $7M | Sell |
79,200
-27,300
| -26% | -$2.25M | 0.14% | 341 |
|
|
2021
Q3 | $8.23M | Buy |
106,500
+1,600
| +2% | +$126K | 0.17% | 276 |
|
|
2021
Q2 | $8.75M | Buy |
104,900
+15,800
| +18% | +$1.25M | 0.18% | 256 |
|
|
2021
Q1 | $6.73M | Sell |
89,100
-7,600
| -8% | -$621K | 0.15% | 343 |
|
|
2020
Q4 | $8.48M | Buy |
96,700
+62,800
| +185% | +$4.98M | 0.19% | 238 |
|
|
2020
Q3 | $2.58M | Sell |
33,900
-17,800
| -34% | -$1.8M | 0.07% | 538 |
|
|
2020
Q2 | $6.38M | Buy |
51,700
+13,400
| +35% | +$1.33M | 0.19% | 199 |
|
|
2020
Q1 | $3.24M | Buy |
38,300
+12,500
| +48% | +$1.08M | 0.12% | 467 |
|
|
2019
Q4 | $2.18M | Buy |
25,800
+7,300
| +39% | +$551K | 0.06% | 608 |
|
|
2019
Q3 | $1.25M | Hold |
18,500
| – | – | 0.04% | 631 |
|
|
2019
Q2 | $1.58M | Sell |
18,500
-1,500
| -8% | -$128K | 0.05% | 633 |
|
|
2019
Q1 | $1.78M | Buy |
+20,000
| New | +$1.85M | 0.05% | 608 |
|
|
2018
Q2 | – | Sell |
-9,800
| Closed | -$794K | – | 645 |
|
|
2018
Q1 | $794K | Buy |
+9,800
| New | +$841K | 0.02% | 643 |
|
|
2016
Q1 | – | Sell |
-6,800
| Closed | -$712K | – | 661 |
|
|
2015
Q4 | $712K | Hold |
6,800
| – | – | 0.02% | 574 |
|
|
2015
Q3 | $716K | Buy |
+6,800
| New | +$908K | 0.02% | 585 |
|
|
2013
Q3 | – | Sell |
-5,710
| Closed | -$319K | – | 557 |
|
|
2013
Q2 | $319K | Buy |
+5,710
| New | +$356K | 0.01% | 546 |
|
Other funds holding BMRN
Andra AP-fonden's BMRN Position: Q4 2025 in Review
Andra AP-fonden sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 142,200 shares — an estimated $7.7M sold.
Andra AP-fonden first reported a position in BMRN in Q2 2013 and held it in 29 quarters. The position peaked at $8.75M in Q2 2021. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Andra AP-fonden reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Andra AP-fonden sold 142,200 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $7.7M.
- Andra AP-fonden first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 29 quarters.
- Andra AP-fonden's BioMarin Pharmaceuticals position peaked at $8.75M in Q2 2021.
- 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Andra AP-fonden's 13F filing for Q4 2025, filed 12 Feb 2026.